Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED ‐HF study
ConclusionOnce NT‐proBNP is included, only hsTnT moderately further improved risk stratification in this group of chronic heart failure with reduced ejection fraction patients with moderate anaemia. NT‐proBNP and hsTnT far outperform other emerging biomarkers in prediction of adverse outcome. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - September 27, 2017 Category: Cardiology Authors: Paul Welsh, Lei Kou, Changhong Yu, Inder Anand, Dirk J. van Veldhuisen, Aldo P. Maggioni, Akshay S. Desai, Scott D. Solomon, Marc A. Pfeffer, Sunfa Cheng, Lars Gullestad, P ål Aukrust, Thor Ueland, Karl Swedberg, James B. Young, Michael W. Kattan, Naveed Tags: Research Article Source Type: research
Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
(Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - September 5, 2017 Category: Urology & Nephrology Source Type: research
De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease
ConclusionsDarbepoetin alfa can be safely administered either QW or Q2W to ESA-na ïve pediatric patients with CKD-related anemia to achieve Hb targets of 10.0–12.0 g/dl. (Source: Pediatric Nephrology)
Source: Pediatric Nephrology - August 17, 2017 Category: Urology & Nephrology Source Type: research
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
CONCLUSIONS: There is low certainty evidence that CERA has little or no effects on patient-centred outcomes compared with placebo, epoetin alfa or beta or darbepoetin alfa for adults with CKD. The effects of CERA among children who have CKD have not studied in RCTs.
PMID: 28782299 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - August 7, 2017 Category: General Medicine Authors: Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study
ConclusionIn cancer patients with chemotherapy-related anemia receiving darbepoetin alfa, sucrosomial oral iron provides similar increase in Hb levels and Hb response, with higher tolerability without the risks or side effects of IV iron. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - July 25, 2017 Category: Cancer & Oncology Source Type: research
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
mp; J Franklin (Source: Leukemia)
Source: Leukemia - July 14, 2017 Category: Hematology Authors: U Platzbecker A Symeonidis E N Oliva J S Goede M Delforge J Mayer B Slama S Badre E Gasal B Mehta J Franklin Source Type: research
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
ConclusionBy clarifying markers and factors involved in ESA hyporesponsiveness and their relationships with renal and CVD events, this ongoing study aims to improve evidence-based therapies for renal anemia in non-dialysis CKD patients. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - June 28, 2017 Category: Urology & Nephrology Source Type: research
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD
Conclusions Most ESRD cases occurred in individuals without intercurrent CV events who had lower eGFRs than individuals with intercurrent CV events, but similar post-ESRD mortality. Nevertheless, intercurrent CV events, particularly heart failure, are strongly associated with risk for ESRD. These findings underscore the need for kidney-specific therapies in addition to treatment of CV risk factors to lower ESRD incidence in diabetes. (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - June 7, 2017 Category: Urology & Nephrology Source Type: research
Carnitine reduced erythropoietin dose required and improved cardiac function of patients on maintenance hemodialysis.
Abstract
Intravenous administration of 2 g carnitine in every hemodialysis (3 times/week), for 8-10 months, reduced doses of darbepoetin alfa required to maintain adequate hemoglobin levels (10-11 g/dL) into 10% of the initial doses. There was also a significant increase in plasma transferrin saturation, increase in left ventricular ejection fraction, and decrease in plasma brain natriuretic peptides.
PMID: 28540882 [PubMed - in process] (Source: Saudi Journal of Kidney Diseases and Transplantation)
Source: Saudi Journal of Kidney Diseases and Transplantation - May 1, 2017 Category: Urology & Nephrology Authors: Aoki Y, Yamamoto T Tags: Saudi J Kidney Dis Transpl Source Type: research
Abstract P2-11-04: Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN)
BackgroundReduced quality of life during chemotherapy is often due to fatigue and dyspnea caused by chemotherapy-induced anemia. In breast cancer patients the incidence is estimated to be above 50% and rising during the course of treatment resulting as well in therapy delays. Despite red blood cell transfusion the administration of erythrocyte stimulating factors (ESF) serves as a treatment option. In comparison with conventional chemotherapy intense dose dense regimens have proven to be beneficial in high-risk breast cancer patients, but higher incidences of anemia have been reported. In the GAIN trial two dose dense regi...
Source: Cancer Research - February 28, 2017 Category: Cancer & Oncology Authors: M van Mackelenbergh, S Loibl, C Jackisch, H–J Luck, A Schneeweiss, H Tesch, N Harbeck, S Schmatloch, T Fehm, J Huober, V Muller, I Bauerfeind, M Untch, G von Minckwitz, V Neklȷudova, V Mobus Tags: Poster Session Abstracts Source Type: research
Evaluation of the Efficacy and Safety of Darbepoetin Alfa in Reducing the Transfusion Requirements in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Hematological Malignancies
We conducted a randomized study analyzing the impact of Darbepoetin Alfa (DA) in reducing transfusion requirements during autologous stem cell transplant. Group A had seventeen patients where darbapoietin alpha was not used. The other group so far has 10 patients. In the later group Darbapoietin was given on Day -14, Day -7 and on day +7, Iv iron was given on day-14, and day -7. We found that the incidence of transfusion requirements have gone down drastically in the DA arm of the study with a mean requirement of .9 units per patient where as previously it was 2.3 units per patient. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 22, 2017 Category: Hematology Authors: Joydeep Chakrabartty, Neelesh Jain, Kasturi Sengupta, Debarghya Mukherjee, Pooja Sarada, Anil Arlbandi, Nitin Sood, Amrita Chakravarti, Amitabh Ray Source Type: research
Abstract P5-07-06: A novel non-canonical Notch1-IKK{alpha}-mTORC2-AKT pathway maintains survival in triple negative breast cancer cells and cancer stem-like cells
BackgroundReduced quality of life during chemotherapy is often due to fatigue and dyspnea caused by chemotherapy-induced anemia. In breast cancer patients the incidence is estimated to be above 50% and rising during the course of treatment resulting as well in therapy delays. Despite red blood cell transfusion the administration of erythrocyte stimulating factors (ESF) serves as a treatment option. In comparison with conventional chemotherapy intense dose dense regimens have proven to be beneficial in high-risk breast cancer patients, but higher incidences of anemia have been reported. In the GAIN trial two dose dense regi...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: F Hossain, Y Peng, A Pannuti, K Backus, T Golde, B Osborne, L Miele Tags: Poster Session Abstracts Source Type: research
Combined Erythropoietin and Iron Therapy for Anemic Patients Undergoing Transcatheter Aortic Valve Replacement: The EPICURE Randomized Clinical Trial.
CONCLUSIONS: EPO administration failed to reduce RC transfusion rate or the per-patient number of transfusion units in anemic patients undergoing TAVI.
PMID: 28067195 [PubMed - as supplied by publisher] (Source: EuroIntervention)
Source: EuroIntervention - January 12, 2017 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 months before Initiation of Hemodialysis: Comparison between Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Abstract
Anemia in chronic kidney disease (CKD) is a risk factor for cardiovascular diseases and is treated by long-acting erythropoiesis-stimulating agents (ESA). Although results of previous studies showed that the hemoglobin level could not be maintained at initiation of dialysis in CKD patients treated with recombinant human erythropoietin, it remains undetermined if long-acting ESA are effective to prevent the progression of anemia at initiation of dialysis. In the present study, hemoglobin levels in 40 CKD patients treated with darbepoetin alfa (DA) and 15 CKD patients treated with a continuous eryth...
Source: The Keio Journal of Medicine - December 18, 2016 Category: Universities & Medical Training Authors: Yoshida T, Hayashi M Tags: Keio J Med Source Type: research
Morbidity, mortality and quality of life in the ageing haemodialysis population: results from the ELDERLY study
Conclusions
In this observational study, the mortality rate of elderly haemodialysis patients was not exceedingly high compared with the age-matched background population. Furthermore, the hospitalization rate was only slightly higher compared with the younger age group and the median yearly hospitalization time trended lower compared with registry data. The social well-being of elderly haemodialysis patients showed a less pronounced decline over time and was equal to the score of the younger cohort at the end of the study period. The physical and functional status in the elderly patients was lower and showed a sharper dec...
Source: CKJ: Clinical Kidney Journal - December 16, 2016 Category: Urology & Nephrology Authors: Seckinger, J., Dschietzig, W., Leimenstoll, G., Rob, P. M., Kuhlmann, M. K., Pommer, W., Fraass, U., Ritz, E., Schwenger, V. Tags: HAEMODIALYSIS Source Type: research
